Difference between revisions of "Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5 (Q9873)"
Jump to navigation
Jump to search
(Created a new Item: #quickstatements; #temporary_batch_1589975872009) |
(Created claim: Page(s) (P105): 6509-6518, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (8 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Kaye SB | ||||||||||||||
| Property / First Author string: Kaye SB / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1158/1078-0432.CCR-12-1796 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 23032746 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2012
| ||||||||||||||
| Property / Publication Date: 2012 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Clin. Cancer Res. | ||||||||||||||
| Property / Published In Name String: Clin. Cancer Res. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 18 | ||||||||||||||
| Property / Volume: 18 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English) | ||||||||||||||
| Property / title: A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 6509-6518 | ||||||||||||||
| Property / Page(s): 6509-6518 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Kaye SB, et al. Clin. Cancer Res. (2012) cited as Ref 610 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Kaye SB
0 references
2012
0 references
Clin. Cancer Res.
0 references
18
0 references
A phase II randomized placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission (English)
0 references
6509-6518
0 references
